↓ Skip to main content

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

Overview of attention for article published in New England Journal of Medicine, September 2013
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Citations

dimensions_citation
2230 Dimensions

Readers on

mendeley
947 Mendeley
citeulike
4 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
Published in
New England Journal of Medicine, September 2013
DOI 10.1056/nejmoa1305889
Pubmed ID
Authors

William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer, Craig Wilson, William C Cushman, Faiez Zannad

Abstract

To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 diabetes who had had a recent acute coronary syndrome.

X Demographics

X Demographics

The data shown below were collected from the profiles of 59 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 947 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 7 <1%
Spain 6 <1%
Netherlands 3 <1%
Germany 3 <1%
United States 3 <1%
Japan 3 <1%
Brazil 2 <1%
Italy 2 <1%
India 1 <1%
Other 7 <1%
Unknown 910 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 132 14%
Other 117 12%
Student > Ph. D. Student 95 10%
Student > Master 79 8%
Student > Bachelor 72 8%
Other 250 26%
Unknown 202 21%
Readers by discipline Count As %
Medicine and Dentistry 491 52%
Pharmacology, Toxicology and Pharmaceutical Science 64 7%
Agricultural and Biological Sciences 48 5%
Biochemistry, Genetics and Molecular Biology 30 3%
Nursing and Health Professions 20 2%
Other 59 6%
Unknown 235 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 777. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 February 2024.
All research outputs
#25,154
of 25,837,817 outputs
Outputs from New England Journal of Medicine
#1,032
of 32,687 outputs
Outputs of similar age
#111
of 213,643 outputs
Outputs of similar age from New England Journal of Medicine
#5
of 294 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,687 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 122.6. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 213,643 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 294 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.